Inclisiran Beats Bempedoic Acid Head-to-Head at ESC 2026, But Cardiovascular Outcomes Gap Persists

Inclisiran Outperforms Bempedoic Acid in LDL-C Lowering

A head-to-head study presented at ESC 2026 revealed that inclisiran demonstrated superior efficacy compared to bempedoic acid in lowering low-density lipoprotein cholesterol (LDL-C) and achieving target attainment. This finding supports the differentiation of inclisiran as a treatment option for high-risk dyslipidaemia patients, despite both drugs being established treatments that reduce LDL-C through distinct mechanisms. The results were published by GlobalData Healthcare on August 31, 2026.

• The study directly compared inclisiran and bempedoic acid, showing inclisiran's superior performance in reducing LDL-C levels. This head-to-head comparison provides clear evidence of one drug's enhanced efficacy over the other in this critical cardiovascular risk factor.
• Beyond just LDL-C lowering, inclisiran also demonstrated better target attainment, which is crucial for managing dyslipidaemia effectively. These results are particularly significant for high-risk patients, offering a potentially more effective therapeutic strategy to achieve desired cholesterol levels.
• The findings from ESC 2026 highlight a key differentiation between inclisiran and bempedoic acid, despite both being established treatments for dyslipidaemia. This distinction, based on superior LDL-C lowering and target attainment, can guide clinical decisions for optimizing patient outcomes.

Navigating the Current Dyslipidaemia Treatment Landscape

Current dyslipidaemia management is governed by a convergence of major international guidelines — including those from the ESC, ACC/AHA, and Canadian Cardiovascular Society — that broadly endorse statin therapy as the cornerstone of both primary and secondary cardiovascular prevention. Guidance has evolved toward a hybrid approach that combines evidence-based statin intensity with defined LDL-C reduction thresholds, stratified by individual cardiovascular risk. Despite accessible and effective therapies, real-world implementation gaps remain a persistent clinical challenge.

• First-line statin therapy and LDL-C targets: Statins remain the foundational treatment for hypercholesterolaemia and hypertriglyceridaemia. European guidelines recommend intensive statin therapy — with ezetimibe added where necessary — to achieve LDL-C <1.8 mmol/L (<70 mg/dL) or ≥50% reduction from baseline in very high-risk patients. Canadian Cardiovascular Society guidelines similarly recommend achieving <2.0 mmol/L or >50% LDL-C reduction.

• Second-line and add-on therapies for hypercholesterolaemia: When LDL-C targets are not met on maximally tolerated statin therapy, ezetimibe is the recommended next step, followed by PCSK9 inhibitors (alirocumab, evolocumab) in very high-risk patients. Inclisiran (a small interfering RNA PCSK9 inhibitor) and bempedoic acid are recognised as safe and effective adjunctive options, and are also appropriate for patients with statin intolerance due to myalgias, rhabdomyolysis, or contraindications. Cost remains a barrier to uptake for underinsured or uninsured patients.

• Second-line therapies for hypertriglyceridaemia: Icosapent ethyl and fenofibrate represent the primary second-line options. While statin–fibrate combination therapy provides more effective control of multiple lipid parameters than either monotherapy alone — with a comparable safety profile — clinical benefit has only been demonstrated in small subgroup analyses, and broader implementation is not yet widely recommended pending further evidence.

• Primary prevention risk stratification: In primary prevention, cardiovascular risk level (low-to-moderate, high, or very high) is the critical determinant of LDL-C treatment targets. Statins should be optimally titrated, with ezetimibe and/or bempedoic acid added as needed to meet objectives, alongside lifestyle modification. Notably, guideline comparison data reveal significant variation in the proportion of patients eligible for lipid-lowering therapy — particularly women — with the 2022 USPSTF and 2021 ESC guidelines leaving nearly half of women who subsequently experienced an incident ASCVD event outside eligibility criteria.

• Risk stratification in elderly patients: In statin-naïve individuals aged ≥70 years, male sex, cumulative LDL-C exposure, and elevated lipoprotein(a) [Lp(a)] were independently associated with coronary artery disease. These findings highlight the potential value of incorporating cumulative LDL-C burden and Lp(a) measurement into risk stratification frameworks for older adults, an area of ongoing clinical debate.

• Real-world implementation gaps: Adherence to guideline-directed therapy remains suboptimal. In one observational cohort, 32.7% of patients with established ASCVD did not achieve the target LDL-C of <2.0 mmol/L or ≥50% reduction from baseline, and only 12.5% were receiving ezetimibe despite its guideline-recommended status as a second-line agent. Systematic optimisation of both statin and non-statin lipid-lowering therapy is essential to close this gap and improve cardiovascular outcomes.

ESC 2026: Inclisiran vs. Bempedoic Acid Trial Design and Outcomes

The pivotal dyslipidaemia trials span a range of therapeutic modalities — from RNA interference and PCSK9 inhibition to GLP-1 receptor agonism and disease management programmes — each with distinct patient populations, randomisation strategies, and endpoint structures. Understanding the granular design parameters of these studies is essential for contextualising their efficacy signals and applicability to clinical practice. The table below consolidates the key design and outcome data across trials.

Differentiating Inclisiran for High-Risk Dyslipidaemia Patients

Despite major advances in lipid-lowering therapy, substantial gaps remain in achieving guideline-recommended LDL-C targets across diverse patient populations. Emerging data highlight several high-priority groups where current therapeutic options are inadequate, costly, or inaccessible — driving a wave of novel mechanistic approaches and treatment strategies.

• Patients not achieving LDL-C goals on statin therapy: A significant proportion of patients — particularly those with type 1 or type 2 diabetes mellitus — fail to reach recommended LDL-C targets despite statin treatment. This persistent dyslipidaemia underscores the need for effective, safe, and practical adjunctive therapies in this population.

• Statin-intolerant patients: Individuals unable to tolerate statins represent a clinically distinct group with elevated and often undertreated cardiovascular risk. The CLEAR Outcomes trial, which enrolled a statin-intolerant population (nearly half of whom had diabetes), reinforced the magnitude of unmet need in this cohort.

• Patients with residual cardiovascular risk beyond LDL-C: Elevated lipoprotein(a) [Lp(a)], apolipoprotein B (apoB), and triglycerides contribute to residual cardiovascular risk inadequately addressed by current therapies. Antisense approaches targeting Lp(a), ANGPTL3 inhibition, and apoC-III inhibition — including in patients with complete lipoprotein lipase deficiency — are actively being investigated to fill this gap.

• Patients with limited access to PCSK9 inhibitors: Despite guideline endorsement for high-risk patients, widespread uptake of injectable PCSK9 inhibitors is constrained by cost, with mixed cost-effectiveness findings across geographies. This has accelerated development of oral PCSK9 inhibitors — including enlicitide decanoate (MK-0616), laroprovstat (AZD0780), and NNC0385-0434 — as potentially more accessible alternatives.

• Familial hypercholesterolaemia (FH): FH remains substantially underdiagnosed, particularly in under-resourced regions such as Central Asia. Next-generation sequencing (NGS) has demonstrated the highest monogenic FH diagnostic yield in patients with a Dutch Lipid Clinic Network (DLCN) score >8, though monogenic FH may be present even in those with probable or possible DLCN scores — highlighting a broader screening opportunity.

• Patients with established ASCVD on maximum tolerated statin therapy: Individuals with established atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains at or above guideline thresholds despite maximum tolerated statins and stable background lipid-lowering therapy represent a core target population, as evidenced by enrolment criteria in recent phase 2 trials of emerging oral agents.